Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole – an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

January 22, 2018

Responsive image

LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it has received  authorization of its Clinical Trial Application fro…

Category: Precious Metals